We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oakleaf 72
As much as I would like to claim moving in celeb circles unfortunately it couldn't be further from the truth
I need to apologise to you and the board for my faux pas the recommendation was written by Mike Payne I simply copied it of the Richards Linkedin page.
Naewise,
I would agree that RM was not his usual ebullient self. As to the reason, one can only speculate. I theorise that he had issues getting the two profs on board; perhaps trying to persuade them to be more positive and up-beat (and failing). Who knows.
But yes, RM usually has more fire with his presentation.
The CCO is certainly a useful addition to the family on various fronts and a TO is certainly within the bounds of possibility. I agree with others that it's surprising there has been no mention of this important appointment. One thing I noticed in the last rather unimpressive webinar was that RM did not seem his usual ebullient self and he appeared a little ill at ease or was this simply my imagination. Perhaps silly to read anything into this but one does wonder if change is afoot.
Good point Edowling. Those were his last words on the matter.
Oakleaf, oh definitely it was some months ago and things could have changed. However, the takeover talks currently are just theories based on bits and bobs of evidence. Officially, all we have heard is what came from RM in that webinar though.
For balance Edowling that webinar was a while ago now and who knows what the landscape looks like to RM now. Talk about moving targets. Of course as an LTH I want what you have suggested but I think it's better to add a little balance in amongst what seems to be extremely good news.
Ghia, I agree RE licensing. RM stated In a previous webinar (the sharesoc one) that as syn have put in all of effort to develop the drug for market, they would be looking at licensing only for covid. They would then look at takeover further down the line.
Personally Invest I think the latter is equally credible. I suspect RM is giving us this but again, purely speculation.
I think they’ve had an internal memo on LinkedIn titles/info following the ‘Interim CFO’ who’s now changed his title following the query someone sent to The business a week or two ago. That, or RM wanted to drop some breadcrumbs out following the dreadful pres and calls for a more commercially focussed approach.
Probably the former.
Just wanted to thank the BB for this excellent discussion and to Oak for his sleuthing!
The naysayers would have you think Syn is bumbling along, not doing much of anything but this goes to show they have a clear vision for how various scenarios might play out.
Still all hinges on trial results but I’m now much more convinced about the scaleability and eventual value we might see here. Once the results are in it’ll be all systems go (hopefully).
Wow Kevkan, that pretty much makes you a celeb here. Tell us more????
Talk about fits the bill what a stonking catch
I worked with Richard, directly and indirectly, for several years at Gilead. As a leader in our Respiratory and Antiviral franchises in both the US and UK, Richard demonstrated true leadership in motivating cross-functional (inc corp dev, R&D, operational) teams to a successful outcome (portfolio growth/ laun..
Interesting replies. The licensing route would surely 'maximise shareholder value' and would earn this product the respect and fair value it deserves after all the heavy lifting we will have done. If I didn't mind waiting it out for an unknown length of time then I'd go this route.
But like it's been mentioned in a few of those replies the clean break sounds far more appealing, and Matt your point about not knowing when to part with your shares and possibly wanting the decision taken out of your hands is one I'm leaning more towards.
As you say Ghia, either way I'm sure we get rewarded but if I were to have a preference I'd go with the takeover purely because I'd have no idea how long a waiting game I'd have to play. Fully understand the marathon strategy though but I'm not sure if it's for me.
Licensing for me... I came in here to run the full Marathon, Not a half Marathon.
I remember back in February 2020, the general consensus was that Synairgen wasn't great at issuing news.
I am waiting for a little traction before topping up. I thought we had bottomed out at £1.25
Good weekend all.
Take over for me. Removes the future risks & unknowns.
Good point re max value mattw007.
Doc - he just updated his LinkedIn profile. So not a news release.
Takeover obviously makes it nice and clear cut and makes the decision on when to sell for you. Likely would bring the quickest value.
Licensing would achieve maximum value for shareholders but could take longer.
Either route will reward investors.
Was also thinking about that Question SeaBoy
Cheers Ghia.
That certainly does make sense, especially from the global approach that's clearly evident here. Don't worry about the hunch - it seems like a well placed one. I'm sure we'll get further clues in due course as to which route we're going.
So while we're on the topic, I know this is a very naive question to be asking this late on but would people here prefer the licensing route or the takeover route? And why?
The gardening leave idea is a possibility, but if he left Verona in Jul it means he would’ve had to resign in Apr. I’m just not convinced Synairgen would’ve been looking for a CCO that early.
Ghia - I too think licensing is their preferred option reason being the Numis broker note and price targets which are based on a licensing arrangement. At least we’ll take the lion share of the covid profits as Synairgen did all the heavy lifting.
Nice to see a fact posted for a change
It's called delegation scinv, it's quite an art, knowing when to let go
I thought I read new synairgen CEO and got excited
Has this guy just started work but hired in Dec or hired in Dec and we've just noticed?
Ghia, I suspect that is a belief widely shared.